Nakagawa K, Garon EB, Seto T, et al. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). ASCO Annual Meeting 2019, abstract 9000.
Gestage groei aantal patiënten met kanker in Nederland
feb 2017 | Borstkanker, Longoncologie, Maag-darm-leveroncologie